ContraVir Pharmaceuticals, Inc. (CTRV) Soars 21% on Positive Clinical Study of Hepatitis B Candidate
Shares of ContraVir Pharmaceuticals (NASDAQ: CTRV) surged in Thursday’s morning trade after the biopharmaceutical company reported positive interim data for CMX157 from its ongoing phase 2a multiple ascending dose clinical study. The head-to-head study is the first evaluation of CMX157 in patients with hepatitis B (HBV), and directly compares CMX157 to tenofovir disoproxil fumarate (TDF, Gilead's Viread®) in chronically infected HBV patients. The CMX157 treated patients showed an average 99% reduction in HBV viral load compared to baseline. "The significant viral load reduction and favorable safety at this low dose of CMX157 speaks to the unique liver-targeting mechanism of our…